Validated Prognostic and Predictive Biomarkers in Breast Cancer
Monogram Biosciences, HERmarkTM Breast Cancer Assay: Prior to acquisition by LabCorp, developed educational slide libraries, white papers, advisory boards, and symposia at ASCO and SABCS
Breast cancer-Roche/Herceptin®; GSK/Tykerb®
Breast cancer diagnostics – Genoptix Medical Laboratory; Monogram Biosciences
Genoptix Medical Laboratory-Novartis/Breast Cancer: Data published by the American Society for Clinical Oncology (ASCO) and the College of American Pathologists (CAP) has demonstrated that 1 in 5 of the results generated by tests commonly used to determine treatment for breast cancer are inaccurate. Community oncologists, who treat 80% of women with breast cancer, lack awareness of this critical issue.
Medical Minds identified and recruited a panel of KOLs from major institutions in the US and UK and worked with them to create a foundational slide library. The slide library will be used in a nationwide educational initiative to educate community oncologists on the appropriate use of breast cancer predictive and prognostic biomarkers in clinical practice.
Breast Cancer Educational Initiative Advisory Panel
Cliff Hudis, MD – Memorial Sloan Kettering
Alan Lipton, MD – Penn State University
Joyce Ann O’Shaughnessy, MD – Texas Oncology
Edith Perez, MD – Mayo Clinic
Hope Rugo, MD – UCSF
Antonio Wolff, MD – Johns Hopkins
Mitch Dowsett, PhD – Royal Marsden, London, UK
David Rimm, MD – Yale University School of Medicine
Baljit Singh, MD, PhD – New York University Medical Center